MDS
Decision Model
Stem Cell Transplantation Is Only Curative Therapy!!!
Timing for HCT Consultation

Adult Leukemias and Myelodysplasia

Myelodysplastic syndromes (MDS)

- Any intermediate or high IPSS or IPSS-R score
- Any MDS with poor prognostic features, including:
  - Treatment-related MDS
  - Refractory cytopenias
  - Adverse cytogenetics
  - Transfusion dependence
  - Failure of hypomethylating agents
Figure 2. Overall survival of patients included in the analysis. (A) Overall survival of the International MDS Risk Assessment Workshop patients who did not undergo autologous stem cell transplantation, stratified by IPSS score at the time of diagnosis ($P < .001$ for differences in risk groups). (B) Overall survival of the IBMTR/FHCRC bone marrow transplantation cohort of patients, stratified by IPSS risk score at the time of transplantation ($P < .001$ for differences in risk groups).
MDS: Timing of HCT Depends on IPSS Score

Overall survival of non-HCT cohorts stratified by low/intermediate (int)-1 and int-2/high IPSS in MDS

Log-rank $P < .001$

Koreth J et al. JCO 2013;31:2662-2670
Overall survival of RIC-HCT cohorts stratified by low/intermediate (int)-1 and int-2/high IPSS in MDS

![Graph showing overall survival over time with two lines representing different IPSS categories.](image)

Log-rank $P = .12$

Koreth J et al. JCO 2013;31:2662-2670
Survival after Unrelated Donor HCT for Myelodysplastic Syndrome (MDS), 2004-2014